.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX14_PolatuzumabVedotin.PolatuzumabVedotin .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX14_PolatuzumabVedotin.PolatuzumabVedotin| name: | PolatuzumabVedotin | |
| ATC code: | L01FX14 | |
| route: | intravenous | |
| compartments: | 2 | |
| dosage: | 1.8 | mg |
| volume of distribution: | 3.15 | L |
| clearance: | 0.9 | L/day |
| other parameters in model implementation | ||
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, used for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It is approved for medical use in several regions including the US and EU.
Population pharmacokinetics in adult patients with relapsed/refractory B-cell lymphoma. Parameters are for acMMAE (antibody-conjugated monomethyl auristatin E component) in predominantly older adults (~61 years, both sexes).
Shemesh, CS, et al., & Lu, D (2020). Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. Cancer chemotherapy and pharmacology 85(5) 831–842. DOI:10.1007/s00280-020-04054-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32222808